» Articles » PMID: 40004650

Current Blood Eosinophilia Does Not Predict the Presence of Pulmonary Hypertension in Patients with End-Stage Lung Disease

Abstract

To investigate the role of blood eosinophils in predicting PH in end-stage lung disease. We conducted a retrospective study of adults with CF, COPD, and ILD who underwent RHC during lung transplant evaluations (2010-2022). Patients were classified by the 2022 ECS/ERS PH guidelines with pulmonary function and laboratory tests, including hemograms. The eosinophil threshold was set at 0.30 G/L. : We analyzed 663 patients (n = 89 CF, n = 294 COPD, and n = 280 ILD). Severe PH was more common in ILD (16%) than in CF (4%) and COPD (7%) ( = 0.0002), with higher eosinophil levels in ILD ( = 0.0002). No significant correlation was found between eosinophil levels and hemodynamic parameters (PAPm, PVR, and CI) across CF, COPD, and ILD (PAPm: = 0.3974, = 0.4400 and = 0.2757, respectively; PVR: = 0.6966, = 0.1489 and = 0.1630, respectively; CI: = 0.9474, = 0.5705 and = 0.5945, respectively), nor was a correlation observed in patients not receiving OCS. Linear regression analysis confirmed the lack of association (PAPm: = 0.3355, = 0.8552 and = 0.4146, respectively; PVR: = 0.6924, = 0.8935 and = 0.5459, respectively; CI: = 0.4260, = 0.9289 and = 0.5364, respectively), controlling for 6-MWD, Nt-proBNP, and ICS/OCS dosages. ROC analysis indicated eosinophils were ineffective in distinguishing PH severity levels across these diseases (AUC 0.54, 0.51, and 0.53, respectively). The analysis of eosinophil levels measured 18 ± 6 months prior to baseline found no predictive correlation with the presence of PH either. Eosinophil levels did not differ significantly among PH groups, but eosinophilic COPD was linked to more unclassified PH, higher CO, and greater lung volumes than non-eosinophilic COPD. In our cohort of end-stage CF, COPD, and ILD patients, blood eosinophilia did not predict the presence of PH but was associated with hemodynamic parameters and lung volumes in COPD.

References
1.
Alzghoul B, As Sayaideh M, Moreno B, Singh S, Innabi A, Reddy R . Pulmonary hypertension in eosinophilic noneosinophilic COPD. ERJ Open Res. 2021; 7(1). PMC: 7938054. DOI: 10.1183/23120541.00772-2020. View

2.
Lin J, Lin S, Zhang Y, Liu W . Identification of Ferroptosis-related potential biomarkers and immunocyte characteristics in Chronic Thromboembolic Pulmonary Hypertension via bioinformatics analysis. BMC Cardiovasc Disord. 2023; 23(1):504. PMC: 10566044. DOI: 10.1186/s12872-023-03511-5. View

3.
Hastie A, Martinez F, Curtis J, Doerschuk C, Hansel N, Christenson S . Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017; 5(12):956-967. PMC: 5849066. DOI: 10.1016/S2213-2600(17)30432-0. View

4.
Kita H . Eosinophils: multifaceted biological properties and roles in health and disease. Immunol Rev. 2011; 242(1):161-77. PMC: 3139217. DOI: 10.1111/j.1600-065X.2011.01026.x. View

5.
Ogbogu P, Rosing D, Horne 3rd M . Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007; 27(3):457-75. PMC: 2048688. DOI: 10.1016/j.iac.2007.07.001. View